ShanghaiJune 1, 2026 /PRNewswire/ — From May 28 to 31, 2026, the 20th Oriental Congress of Cardiology, hosted by the Shanghai Medical Association and the Shanghai Medical Association Cardiovascular Disease Branch, was held in Shanghai. During the event, Genesis MedTech hosted the “AI-Guided Intervention • Technology Innovation Forum,” which brought together leading experts in the field of interventional therapy in China to discuss the integration of current interventional treatments and artificial intelligence technology.
At the start of the forum, Academician Wang Jian’an from the Second Affiliated Hospital of Zhejiang University School of Medicine noted in his opening address that AI technology has moved from concept to clinical application, truly beginning to assist doctors. As early as last year, the Second Hospital of Zhejiang University utilized AI-empowered angiography to calculate blood flow, aiding in the decision of whether to implant a cardiac stent in patients. Compared to traditional intravascular ultrasound technology, this reduced unnecessary cardiac stent implants by 11.5%.
Professor Wu Yongjian’s team from Fuwai Hospital, Chinese Academy of Medical Sciences, delivered a keynote speech titled “AI-Empowered Medical Transformation: Frontier Exploration in the Field of Heart Valve Disease.” The speech highlighted significant progress in the application of AI throughout the full disease management of valvular heart disease.
Valvular heart disease is often insidious in its early stages, with conventional echocardiographic screening being labor-intensive and subject to variability in observer experience. The intervention of AI technology is reshaping screening models. For instance, AI electronic stethoscopes, by identifying heart murmurs, achieve a sensitivity of 86% and specificity of 100% in diagnosing moderate to severe aortic stenosis. They offer portability and cost-effectiveness, making them suitable for large-scale screening in primary healthcare institutions. In the treatment phase, a deep learning-based preoperative CT image analysis system for transcatheter aortic valve replacement (TAVR) can fully automatically and accurately analyze core anatomical dimensions within one minute, providing relevant surgical risk factor prompts. Validation shows high consistency with manual measurements by senior physicians in core laboratories.
Professor Xu Jizhe from the First Hospital of Lanzhou University focused on the innovative application and clinical practice of imaging technology in interventional treatment of structural heart disease, sharing his team’s clinical experience with surgical imaging strategies such as multimodal image fusion. He also looked ahead to AI-assisted image analysis helping interventional medicine transition from “seeing clearly” to “seeing accurately.” Whether it is precise assessment of coronary lesions, fine navigation of intracranial vessels, or three-dimensional reconstruction of peripheral vessels, AI image fusion technology will play a crucial role.
Concurrently, Genesis MedTech and Philips Healthcare held a strategic signing ceremony to jointly promote innovative solutions for AI-assisted intraoperative guidance in next-generation vascular interventions. Genesis MedTech’s product portfolio covers coronary intervention, neurointervention, peripheral intervention, and structural heart disease. This cross-sector collaboration signifies that medical device companies and imaging companies are expanding their respective boundaries, engaging in deeper and broader exploration around interventional devices, imaging equipment, and AI applications. This is expected to accelerate the intelligent upgrade of vascular interventional diagnosis and treatment.